Qyuns Therapeutics Co (HKSE:02509) Operating Margin %: 58.97% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02509 Qyuns Therapeutics Co Ltd HKSE:02509
9 GF Score
Price HK$17.64
! 5 Warning Signs
View Full Analysis

What is Qyuns Therapeutics Co Operating Margin %?

Qyuns Therapeutics Co HKSE:02509 -1.84% 9 Operating Margin % is 58.97% as of Dec. 2025. GuruFocus rates HKSE:02509 with a GF Score™ of 9/100. The stock has 5 warning signs investors should review. Among 943 Biotechnology companies, Qyuns Therapeutics Co ranks better than 95.97% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Qyuns Therapeutics Co's Operating Income for the six months ended in Dec. 2025 was HK$391.2 Mil. Qyuns Therapeutics Co's Revenue for the six months ended in Dec. 2025 was HK$663.4 Mil. Therefore, Qyuns Therapeutics Co's Operating Margin % for the quarter that ended in Dec. 2025 was 58.97%.

The historical rank and industry rank for Qyuns Therapeutics Co's Operating Margin % or its related term are showing as below:

HKSE:02509' s Operating Margin % Range Over the Past 10 Years
Min: -215.52   Med: -87.12   Max: 41.43
Current: 41.43


HKSE:02509's Operating Margin % is ranked better than
95.97% of 943 companies
in the Biotechnology industry
Industry Median: -83.62 vs HKSE:02509: 41.43

Qyuns Therapeutics Co's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Qyuns Therapeutics Co's Operating Income for the six months ended in Dec. 2025 was HK$391.2 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was HK$368.4 Mil.

Warning Sign:

Qyuns Therapeutics Co Ltd had lost money in 67% of the time over the past 3quarters.


Qyuns Therapeutics Co  (HKSE:02509) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Qyuns Therapeutics Co Operating Margin % Related Terms


Qyuns Therapeutics Co Operating Margin % Historical Data

* Premium members only.

The historical data trend for Qyuns Therapeutics Co's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qyuns Therapeutics Co Operating Margin % Chart

Qyuns Therapeutics Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
0.00 0.00 0.00 -215.52 41.29

Qyuns Therapeutics Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Operating Margin % Get a 7-Day Free Trial 0.00 -383.50 -149.25 -10.11 58.97

HKSE:02509 vs VRTX, REGN, RVMD: Operating Margin % Comparison

For the Biotechnology subindustry, Qyuns Therapeutics Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qyuns Therapeutics Co Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Qyuns Therapeutics Co's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Qyuns Therapeutics Co's Operating Margin % falls into.


HKSE:02509
9GF Score
Qyuns Therapeutics Co Ltd HKSE:02509
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Qyuns Therapeutics Co Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Qyuns Therapeutics Co's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=368.109 / 891.47
=41.29 %

Qyuns Therapeutics Co's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=391.173 / 663.36
=58.97 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 58.97% mean?
Qyuns Therapeutics Co (HKSE:02509) has a Operating Margin % of 58.97% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Qyuns Therapeutics Co and its competitors. According to the industry distribution chart, Qyuns Therapeutics Co ranks #38 out of 943 companies in the Biotechnology industry, placing it in the top 4%.
Is Qyuns Therapeutics Co's Operating Margin % too high?
Qyuns Therapeutics Co's current Operating Margin % is 58.97%. Based on the distribution chart, Qyuns Therapeutics Co ranks #38 out of 943 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Qyuns Therapeutics Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Qyuns Therapeutics Co's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Qyuns Therapeutics Co ranks #38 out of 943 companies for Operating Margin %. This places Qyuns Therapeutics Co in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Qyuns Therapeutics Co and its competitors. Qyuns Therapeutics Co's current Operating Margin % is 58.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qyuns Therapeutics Co stock overvalued right now?
Qyuns Therapeutics Co (HKSE:02509) has a current Operating Margin % of 58.97%. The current Operating Margin % is 58.97%. Qyuns Therapeutics Co's overall GF Score™ is 9/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Qyuns Therapeutics Co (HKSE:02509), the current Operating Margin % is 58.97% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Qyuns Therapeutics Co Business Description

Address No. 907 Yaocheng Avenue, Room 1310, Building 1, Taizhou, Jiangsu, CHN
Qyuns Therapeutics Co Ltd is a clinical-stage biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline. It has built a pipeline that covers the four disease areas in the field, including skin, rheumatic, respiratory, and digestive diseases. The group is principally engaged in the research and development, manufacturing, and commercialisation of biologic therapies for autoimmune and allergic diseases. Key revenue is generated from the PRC.
9GF Score

Get the complete analysis for HKSE:02509

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$17.64
Price